November 9, 2021
3:00PM-4:00PMET

Webinar

About The Event

2022 will bring a continued focus on orphan drugs, anticipated specialty blockbusters and specialty drug approvals shaped by regulatory dynamics. Join Bill Dreitlein, senior director, drug pipeline and surveillance at OptumRx as he shares how these changing dynamics of specialty pharmacy will affect employers in 2022 and beyond.

Sponsored by

Speaker Details

Bill Dreitlein

Senior Director of Pipeline and Drug Surveillance, OptumRx

Bill oversees a team of pharmacists that evaluates the drug development pipeline for new therapies, tracks FDA-mandated drug recalls and monitors drug shortages.

Bill brings over 25 years of health care experience in multiple environments including academia, managed care, hospital, medical advertising and health technology assessment. Prior to joining OptumRx Bill was director of pharmaceutical intelligence at the Institute or Clinical and Economic Review (ICER) an independent, non-profit organization focused on health technology assessment and drug pricing.

Bill holds PharmD and BS degrees from Rutgers University. He also completed a post-graduate residency in Drug Information Practice at the University of Maryland, School of Pharmacy.